# A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

> **NCT01916447** · PHASE1 · COMPLETED · sponsor: **Taiho Oncology, Inc.** · enrollment: 65 (estimated)

## Conditions studied

- Advanced Gastrointestinal Tumors

## Interventions

- **DRUG:** TAS-102
- **DRUG:** CPT-11
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01916447
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01916447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01916447, "A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01916447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*